Wall Street brokerages expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to post $3.71 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Progenics Pharmaceuticals’ earnings. The highest sales estimate is $3.80 million and the lowest is $3.62 million. Progenics Pharmaceuticals posted sales of $3.19 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 16.3%. The firm is expected to report its next earnings results on Wednesday, May 8th.
On average, analysts expect that Progenics Pharmaceuticals will report full year sales of $35.93 million for the current financial year, with estimates ranging from $35.76 million to $36.10 million. For the next financial year, analysts anticipate that the business will post sales of $77.12 million, with estimates ranging from $55.84 million to $98.40 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Progenics Pharmaceuticals.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.14). The company had revenue of $3.24 million for the quarter, compared to the consensus estimate of $10.99 million. Progenics Pharmaceuticals had a negative net margin of 433.09% and a negative return on equity of 59.85%.
Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. grew its holdings in shares of Progenics Pharmaceuticals by 2,466.1% in the fourth quarter. Advisor Group Inc. now owns 12,651 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 12,158 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Progenics Pharmaceuticals in the third quarter valued at $102,000. Fosun International Ltd grew its holdings in shares of Progenics Pharmaceuticals by 14.0% in the fourth quarter. Fosun International Ltd now owns 454,588 shares of the biotechnology company’s stock valued at $1,773,000 after purchasing an additional 56,000 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of Progenics Pharmaceuticals by 6.9% in the third quarter. Teachers Advisors LLC now owns 241,655 shares of the biotechnology company’s stock valued at $1,515,000 after purchasing an additional 15,696 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Progenics Pharmaceuticals by 9.2% in the third quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock valued at $7,277,000 after purchasing an additional 97,561 shares in the last quarter. Hedge funds and other institutional investors own 87.59% of the company’s stock.
Shares of Progenics Pharmaceuticals stock traded down $0.01 on Monday, hitting $4.85. 776,847 shares of the company traded hands, compared to its average volume of 1,256,214. The stock has a market cap of $410.03 million, a P/E ratio of -7.70 and a beta of 2.45. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.15 and a quick ratio of 6.15. Progenics Pharmaceuticals has a 52 week low of $3.62 and a 52 week high of $9.42.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Featured Story: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.